Dr. Martens Plc (GB:DOCS) has released an update.
Dr. Martens Plc has reported a tough fiscal year 2024, with a 12% drop in revenue influenced by weak consumer demand in the USA, particularly affecting wholesale business. Despite challenges, the company saw a 7% increase in direct-to-consumer sales and is initiating a cost savings plan to target £20m-£25m in savings. The company remains committed to driving demand and growth in the USA with a detailed marketing plan and cost action strategy.
For further insights into GB:DOCS stock, check out TipRanks’ Stock Analysis page.
